Advertisement

Topics

I'm hesitant to get excited about this upcoming STING data because it reminds me of when Bristol and FivePrime talked up the first CSF-1R data ahead of SITC last year. But it is a little unusual for Merck to focus on something brand new like this as much

19:33 EDT 13 Oct 2018 | Brad Loncar

I'm hesitant to get excited about this upcoming STING data because it reminds me of when Bristol and FivePrime talked up the first CSF-1R data ahead of SITC last year. But it is a little unusual for Merck to focus on something brand new like this as much as they have been.

Original Article: I'm hesitant to get excited about this upcoming STING data because it reminds me of when Bristol and FivePrime talked up the first CSF-1R data ahead of SITC last year. But it is a little unusual for Merck to focus on something brand new like this as much

NEXT ARTICLE

More From BioPortfolio on "I'm hesitant to get excited about this upcoming STING data because it reminds me of when Bristol and FivePrime talked up the first CSF-1R data ahead of SITC last year. But it is a little unusual for Merck to focus on something brand new like this as much "

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...